Tumor-associated antigens on autologous follicular lymphoma cells

Tumor-associated antigens on autologous follicular lymphoma cells primarily refer to the patient-specific idiotype (Id) of the surface immunoglobulin expressed by malignant B-cell clones (Levy & Miller, 1990). Because follicular lymphoma is a monoclonal proliferation, the unique variable region of the B-cell receptor serves as a highly specific neoantigen that is not present on healthy B-cells (Schuster et al., 2011). These antigens are the basis for personalized immunotherapy, where the idiotype is harvested from the patient's own tumor cells and used to create autologous vaccines (Inogès et al., 2006). The goal of targeting these antigens is to stimulate a robust, tumor-specific immune response, including both cytotoxic T-lymphocytes and anti-idiotype antibodies, to eliminate minimal residual disease (Bendandi et al., 1999). Despite the high specificity of this approach, its clinical application has been challenged by the logistical demands of custom manufacturing and mixed results in large-scale phase III trials (Schuster et al., 2011; Freedman, 2009).

Other names

Follicular lymphoma idiotypeAutologous tumor-derived idiotypePatient-specific tumor antigensId-KLHTumor-specific idiotype

Active immunotherapy involving the administration of patient-specific antigens, typically the tumor idiotype conjugated to a carrier protein like KLH, to induce a polyclonal T-cell and B-cell mediated immune response against the malignant B-cell clone (Schuster et al., 2011; Inogès et al., 2006).